Olfactory identification deficits in first-episode psychosis may predict patients at risk for persistent negative and disorganized or cognitive symptoms

The American Journal of Psychiatry
Kimberley P GoodL Kopala

Abstract

One-third of patients with a schizophrenia spectrum disorder have a measurable olfactory identification deficit at first examination. The authors studied the relationship of this deficit to symptom remission after 1 year of treatment. Fifty-eight patients naive to antipsychotic medication who entered the Nova Scotia Early Psychosis Program were symptomatically rated with the Positive and Negative Syndrome Scale (PANSS) (at baseline and 1 year). At baseline, the University of Pennsylvania Smell Identification Test (UPSIT) was also completed. Remission was determined for four symptom factors derived from the PANSS (positive, negative, cognitive/disorganized, and anxiety/depression). Patients with and without remission were compared on UPSIT scores. Patients with nonremission of negative and cognitive/disorganized symptoms had significantly lower baseline UPSIT scores compared with patients with remission. UPSIT scores were unrelated to remission of positive or anxiety/depression symptoms. UPSIT scores can be used to identify patients at risk for persistent negative and disorganized/cognitive symptoms.

Citations

Sep 5, 2008·Journal of Neurology·Stephanie KrügerThomas Hummel
Jul 19, 2012·Journal of Neural Transmission·Martin SchecklmannMarcel Romanos
Mar 11, 2011·Cognitive Neuropsychiatry·Vidyulata KamathMichael T Compton
Jan 7, 2010·Current Opinion in Psychiatry·Claudia I Rupp
Jul 17, 2013·International Journal of Psychophysiology : Official Journal of the International Organization of Psychophysiology·Jürgen KayserCheryl M Corcoran
Feb 8, 2013·Clinical Toxicology : the Official Journal of the American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists·Michael I GreenbergDavid Vearrier
Jan 8, 2009·Autoimmunity·Oscar-Danilo Ortega-HernandezYehuda Shoenfeld
Feb 29, 2016·Pharmacological Reports : PR·Justyna Pełka-WysieckaJerzy Samochowiec
Aug 21, 2007·Schizophrenia Research·Kimberley P GoodLili C Kopala
May 7, 2011·The British Journal of Clinical Psychology·Robyn LangdonStanley V Catts
Nov 18, 2006·Autoimmunity Reviews·Rael D Strous, Yehuda Shoenfeld
Nov 11, 2011·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Vidyulata KamathPaul J Moberg
Oct 22, 2016·Schizophrenia Research·Magdalena Kotlicka-AntczakMałgorzata Urban-Kowalczyk
Jun 25, 2017·Neuroscience and Biobehavioral Reviews·Angela IannitelliGiuseppe Bersani
Oct 6, 2017·Schizophrenia Bulletin·Vidyulata KamathAkira Sawa
Oct 27, 2017·European Archives of Psychiatry and Clinical Neuroscience·Tsutomu TakahashiMichio Suzuki
Nov 2, 2018·European Archives of Oto-rhino-laryngology : Official Journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : Affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery·Neşe AsalSadiye Visal Buturak
Jan 16, 2008·The Journal of Nervous and Mental Disease·César González-BlanchBenedicto Crespo-Facorro
Mar 6, 2018·European Psychiatry : the Journal of the Association of European Psychiatrists·Gabriele CheliniSabina Berretta
Sep 10, 2010·Harvard Review of Psychiatry·An D NguyenJames J Levitt
Jan 12, 2020·Schizophrenia Research·Anna Hester Ver Loren van ThemaatJens Richardt Møllegaard Jepsen
Sep 1, 2021·Seminars in Cell & Developmental Biology·Sue KulasonAkira Sawa

❮ Previous
Next ❯

Software Mentioned

UPSIT

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here